期刊文献+

异丙酚在感染性休克中的应用进展 被引量:1

原文传递
导出
摘要 感染性休克是以全身性感染导致器官功能损害为特征的复杂临床综合征,在其过程中,由于感染后体内炎症介质如肿瘤坏死因子(TNF)、自细胞介素-1(IL-1)、前列腺素和一氧化氮(NO)大量释放,α受体兴奋性下降以及大量三磷酸腺苷敏感性钾离子(K^+ ATP)通道被激活等因素,体循环始终处于扩张状态,实质为血管扩张性休克,表现特点为体循环阻力明显下降,有效循环血量减少,
出处 《中国危重病急救医学》 CAS CSCD 北大核心 2009年第5期317-319,共3页 Chinese Critical Care Medicine
基金 辽宁省沈阳市重点应用基础课题(071021)
  • 相关文献

参考文献20

二级参考文献51

  • 1洪方晓,李树人.异丙酚对大鼠缺氧性肺血管收缩反应的影响[J].中华麻醉学杂志,2004,24(12):909-912. 被引量:9
  • 2谭敦勇,张继峰,牛大地,迟学栋,陈晓彤,张越,赵云涛,石湘云,汤健,唐朝枢.降钙素基因相关肽拮抗内皮素生物效应的研究[J].中国病理生理杂志,1993,9(5):653-657. 被引量:100
  • 3艾宇航,张丽娜,龚华,徐道妙,赵双平,陈江辉.低分子肝素治疗脓毒症的前瞻性临床研究[J].中国危重病急救医学,2005,17(12):736-739. 被引量:43
  • 4苏艳丽,王红,张淑文.脓毒症的凝血功能紊乱与抗凝治疗研究进展[J].中国危重病急救医学,2006,18(11):698-701. 被引量:45
  • 5潘景业(综述),陈洁(综述).抗凝抗炎抗休克治疗的进展[J].中国危重病急救医学,2007,19(5):318-320. 被引量:2
  • 6Angus D C,Linde-Zwirble W T,Lidicker J,et al. Epidemiology of severe sepsis in the United States. analysis of incidence, outcome, and associated costs of care [J]. Crit Care Med, 2001,29 (7) : 1303-1310.
  • 7American College of Chest Physicians/ Society of Critical Care Medicine Consensus Conference: definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis[J]. Crit Care Med, 1992,20 (6):864-874.
  • 8Levi M,van der Poll T. Two-way interactions between inflammation and coagulation[J] Trends Cardiovasc Med, 2005,15(7) : 254-259.
  • 9Bernard G R,Vincent J L,Laterre P F, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis [J]. N Engl J Med, 2001, 344 (10) :699-709.
  • 10Smithies M N,Weaver C B. Role of the tissue factor pathway in the pathogene- sis and management of multiple organ failure[J]. Blood Coagul Fibrinolysis, 2004,15 Suppl 1:S11-20.

共引文献67

同被引文献16

  • 1Carrasco G,Cabré L,Sobrepere G. Synergistic sedation with propofol and midazolam in intensive care patients after coronary artery bypass grafting[J].Critical Care Medicine,1998.844-851.
  • 2Farling PA,Johnston JR,Coppel DL. Propofol infusion for sedation of patients with head injury in intensive care.A preliminary report[J].Anaesthesia,1989.222-226.
  • 3Matta B,Menon D. Severe head injury in the United Kingdom and Ireland:a survey of practice and implications for management[J].Critical Care Medicine,1996.1743-1748.
  • 4Sanchez-Izquierdo-Riera JA,Caballero-Cubedo RE,Perez-Vela JL. Propofol versus midazolam:safety and efficacy for sedating the severe trauma patient[J].Anesthesia and Analgesia,1998.1219-1224.
  • 5Ramsay MA,Savege TM,Simpson BR. Controlled sedation with alphaxalone-alphadolone[J].British Medical Journal,1974.656-659.
  • 6Weinbroum AA,Halpern P,Rudick V. Midazolam versus propofol for long-term sedation in the ICU:a randomized prospective comparison[J].Intensive Care Medicine,1997.1258-1263.
  • 7Barrientos-Vega R,Mar Sánchez-Soria M,Morales-García C. Prolonged sedation of critically ill patients with midazolam or propofol:impact on weaning and costs[J].Critical Care Medicine,1997.33-40.
  • 8Albanese J,Martin C,Lacarelle B. Pharmacokinetics of long-term propofol infusion used for sedation in ICU patients[J].Anesthesiology,1990.214-217.
  • 9Aitkenhead AR,Pepperman ML,Willatts SM. Comparison of propofol and midazolam for sedation in critically ill patients[J].The Lancet,1989.704-709.
  • 10Eddleston JM,Pollard BJ,Blades JF. The use of propofol for sedation of critically ill patients undergoing haemodiafiltration[J].Intensive Care Medicine,1995.342-347.

引证文献1

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部